Gelteq Ltd (GELS) News

Gelteq Appoints Dr. Paul Wynne as Chief Scientific Officer to Propel Innovative Ingestible Gel Technology

NEW YORK, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Gelteq Receives FDA Approval of its Suitability Petition for New Animal Drug

NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Gelteq to Participate in the Benchmark Company 13th Annual Discovery Investor Conference

NEW YORK, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Gelteq Announces Largest U.S. Customer Increases Initial Order by 50% to Meet Growing Market Demand

NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Gelteq Announces 400,000 Units Enter into Production in November 2024

NEW YORK, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]

Gelteq Expands Operations in United States with Appointment of Adam Bendell as President of U.S. Operations to Scale Domestic Business

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (NASDAQ: GELS) (“Gelteq” or the “Company”), a...

Form NT 20-F - Notification of inability to timely file Form 20-F

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

Gelteq Limited Closes US$5.2 Million Initial Public Offering

NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global...

Gelteq Limited Prices US$5.2 Million Initial Public Offering

NEW YORK, Oct. 28, 2024 (GLOBE NEWSWIRE) -- Gelteq Limited (“Gelteq” or the “Company”), a global...